ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials

Oric Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.37

Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.
R&D expenses $22.0M in Q1 2024 vs $19.5M in Q1 2023; G&A $7.0M vs $6.2M.
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC with EGFR/HER2 mutations; updated data expected H1 2025.
ORIC-944 initial Phase 1b data supports best-in-class profile; proceeding to combination with AR inhibitor in metastatic prostate cancer.
Strengthened cash with $125M private placement in January 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oric Pharmaceuticals, Inc. reported financial results for for the quarter ended March 31, 2024.

Period: for the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.